Welcome to our dedicated page for Taro Pharmaceutical Inds news (Ticker: TARO), a resource for investors and traders seeking the latest updates and insights on Taro Pharmaceutical Inds stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Taro Pharmaceutical Inds's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Taro Pharmaceutical Inds's position in the market.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) will release its financial results for the second quarter ended September 30, 2022, on Thursday, October 27, 2022, after the market closes. Investors can access the release on Taro’s official website, which aims to provide high-quality healthcare products through its comprehensive pipeline. This announcement sets the stage for analyzing Taro's financial performance as the company continues to focus on its growth strategy and market demands.
Galderma reported a robust financial performance in the first half of 2022, with net sales increasing by 15% year-on-year to 1,914 million USD. Key drivers included strong growth in Injectable Aesthetics (+32%) and Dermo-cosmetics (+31%). The company remains on track to achieve its 2022 guidance of 12-14% growth in net sales and core EBITDA. Galderma's pipeline includes successful clinical milestones and innovative product launches, including the first ready-to-use botulinum toxin in Europe and significant expansions in key markets like China and India.
Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall of six lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL due to potential contamination with particulate matter. The recall is carried out with Health Canada's awareness, although there have been no reports of serious adverse events linked to these products. Consumers holding affected vials are advised to return them to their pharmacies. The recalled lots include batch numbers JKX1910A, JKX4318A, JKX5541A, HAC2371A, HAC4421A, and HAD0156A, with expiry dates ranging from April 2023 to January 2025.
Taro Pharmaceutical Industries Ltd. reported unaudited financial results for the quarter ended June 30, 2022, showing a 6.5% increase in net sales to $156.7 million compared to the same quarter last year. The gross profit was $81.6 million, representing 52.1% of net sales. Operating income improved to $14.0 million, a turnaround from a loss of $(19.2) million. Net income was $14.1 million versus a loss of $(18.8) million, yielding earnings per share of $0.37. However, cash flow used in operations was $58.0 million, with a significant decline in cash and cash equivalents to $1.18 billion.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) has made its Annual Report on Form 20-F for the fiscal year ending March 31, 2022, available on its Investor Relations website. Stakeholders may access the report online or request free hard copies. This report outlines Taro's commitment to providing quality healthcare products through its research and development efforts. The document can also be found on the SEC's website. For more details, visit www.taro.com.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) will release its financial results for Q1 ending June 30, 2022, on July 27, 2022, after market close. This release will be available on www.taro.com.
The company focuses on providing high-quality healthcare products, emphasizing discovery, development, and manufacturing.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) reported its financial results for the quarter and year ended March 31, 2022. Net sales for Q1 were $143.3 million, a $5.1 million decrease, while net income reached $27.4 million versus a loss of $(29.8) million. The year saw net sales of $561.3 million, an increase of $12.4 million, and net income of $58.3 million compared to a loss of $(386.7) million. R&D expenses declined, but SG&A expenses rose significantly. A recent acquisition of Alchemee for $91.9 million was completed. The company continues to navigate market challenges while focusing on growth and development.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) will release its financial results for the year ended March 31, 2022, on May 26, 2022, after market close. Investors can access the details on Taro's official website. The company focuses on developing, manufacturing, and marketing high-quality healthcare products globally. This announcement sets the stage for an evaluation of the company's financial performance, which could impact investor sentiment and stock performance.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) has successfully acquired Alchemee, the former Proactiv Company, from Galderma. This acquisition includes Alchemee's global business and assets, notably the Proactiv brand, a leading acne care solution for over 25 years. CEO Uday Baldota highlighted that this move reinforces Taro's position in over-the-counter dermatology and adds marketing capabilities from Alchemee. Alchemee's Global Head, Shannon Pappas, expressed confidence that this strategic acquisition will foster growth in skincare.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) has entered into a definitive agreement to acquire Alchemee, the former Proactiv Company, from Galderma. The acquisition includes Alchemee’s global business and the renowned Proactiv® brand, which has been trusted for acne care for over 25 years. Taro's CEO expressed excitement about the acquisition, emphasizing a commitment to addressing acne treatment for millions globally. The transaction is subject to customary closing conditions and regulatory approvals, with financial terms not disclosed.